<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Capsular warning syndrome (CWS) carries a significant risk of permanent <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>There are no proven therapies for preventing completed <z:hpo ids='HP_0001297'>stroke</z:hpo> in this unstable situation </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Clinical observation in two patients with aspirin-resistant CWS treated with a loading dose of oral <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Both patients had excellent neurological outcome, although one sustained an asymptomatic <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: High-dose oral <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> plus aspirin merits formal evaluation in high-risk transient <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> such as CWS, preferably in a randomized trial compared to aspirin alone </plain></SENT>
</text></document>